Lexston Life Sciences Corp. (LEXTF)
USD 0.13
(83.92%)
USD 0.13
(83.92%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 | -674.71 Thousand CAD | 22.58% |
| 2023 | -674.71 Thousand CAD | 49.95% |
| 2022 | -1.58 Million CAD | -264.55% |
| 2021 | -433.42 Thousand CAD | -6588.65% |
| 2020 | -6480.00 USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -83.16 Thousand CAD | -100.3% |
| 2024 Q4 | -113.04 Thousand CAD | 69.67% |
| 2024 Q2 | -101.83 Thousand CAD | -22.91% |
| 2024 Q3 | -372.68 Thousand CAD | -169.71% |
| 2023 Q4 | -51.63 Thousand CAD | 76.88% |
| 2023 FY | -790.76 Thousand CAD | 49.95% |
| 2023 Q3 | -223.36 Thousand CAD | 26.77% |
| 2023 Q2 | -305.03 Thousand CAD | -38.56% |
| 2023 Q1 | -220.13 Thousand CAD | 25.18% |
| 2022 FY | -1.58 Million CAD | -264.55% |
| 2022 Q2 | -513 Thousand CAD | -21.31% |
| 2022 Q1 | -422.87 Thousand CAD | 0.0% |
| 2022 Q3 | -365.52 Thousand CAD | 28.75% |
| 2022 Q4 | -294.2 Thousand CAD | 19.51% |
| 2021 FY | -433.42 Thousand CAD | -6588.65% |
| 2021 Q3 | 102.34 Thousand CAD | 920.22% |
| 2021 Q2 | -12.47 Thousand CAD | 0.0% |
| 2020 FY | -6480.00 USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Evofem Biosciences, Inc. | -17.84 Million USD | 96.219% |
| Arch Therapeutics, Inc. | -5.04 Million USD | 86.625% |
| CSL Limited | 3.7 Billion USD | 100.018% |
| Santhera Pharmaceuticals Holding AG | 81.85 Million USD | 100.824% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | 1.781% |
| BioStem Technologies, Inc. | -7.77 Million USD | 91.326% |
| Capstone Therapeutics Corp. | -1.25 Million USD | 46.28% |
| Qrons Inc. | -643.67 Thousand USD | -4.822% |
| Nascent Biotech, Inc. | -2.22 Million USD | 69.742% |
| Northwest Biotherapeutics, Inc. | -55.5 Million USD | 98.784% |
| Oncotelic Therapeutics, Inc. | -6.64 Million USD | 89.851% |
| Skye Bioscience, Inc. | -13.67 Million USD | 95.065% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | -62.395% |
| Rebus Holdings, Inc. | -664 Thousand USD | -1.614% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | 95.748% |
| Burzynski Research Institute, Inc. | -1.33 Million USD | 49.476% |
| Genscript Biotech Corporation | -415.79 Million USD | 99.838% |
| Neon Bloom, Inc. | -389.57 Thousand USD | -73.196% |
| Adynxx, Inc. | - USD | Infinity% |
| Eiger BioPharmaceuticals, Inc. | -71.78 Million USD | 99.06% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | 113.728% |
| Institute of Biomedical Research Corp. | -261.72 Thousand USD | -157.796% |
| SQZ Biotechnologies Company | -75.82 Million USD | 99.11% |
| Intellipharmaceutics International Inc. | -2.85 Million USD | 76.33% |
| Propanc Biopharma, Inc. | -1.53 Million USD | 56.074% |
| Mesoblast Limited | -84.14 Million USD | 99.198% |
| Marizyme, Inc. | -34.08 Million USD | 98.021% |
| Genus plc | 6.4 Million USD | 110.542% |
| VioQuest Pharmaceuticals, Inc. | 9.74 Million USD | 106.926% |
| Pharming Group N.V. | -4.87 Million USD | 86.173% |
| Therapeutic Solutions International, Inc. | -1.98 Million USD | 66.034% |
| CNBX Pharmaceuticals Inc. | -931.38 Thousand USD | 27.557% |
| Nymox Pharmaceutical Corporation | -8.35 Million USD | 91.92% |
| ContraFect Corporation | -56.88 Million USD | 98.814% |
| PsyBio Therapeutics Corp. | -4.55 Million USD | 85.186% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | 51.874% |
| IMV Inc. | -38.67 Million USD | 98.255% |
| AXIM Biotechnologies, Inc. | -2.75 Million USD | 75.472% |
| MultiCell Technologies, Inc. | -722.81 USD | -93246.523% |
| ONE Bio Corp. | 13.68 Million USD | 104.932% |
| Accustem Sciences Inc. | -3.74 Million USD | 81.99% |
| RVL Pharmaceuticals plc | -58.99 Million USD | 98.856% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| EV Biologics, Inc. | -483.06 Thousand USD | -39.675% |
| Q BioMed Inc. | -3.44 Million USD | 80.418% |
| Emmaus Life Sciences, Inc. | 3.54 Million USD | 119.06% |
| Mosaic ImmunoEngineering Inc. | -2.62 Million USD | 74.321% |
| Biomind Labs Inc. | -1 Million USD | 33.17% |
| American Oriental Bioengineering, Inc. | -54.97 Million USD | 98.773% |
| Provectus Biopharmaceuticals, Inc. | -2.9 Million USD | 76.744% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| GlobeStar Therapeutics Corporation | -1.86 Million USD | 63.81% |
| THC Farmaceuticals, Inc. | -29.95 Thousand USD | -2152.664% |
| Curative Biotechnology, Inc. | -1.93 Million USD | 65.088% |
| GB Sciences, Inc. | -1.42 Million USD | 52.502% |
| Alpha Cognition Inc. | -9.7 Million USD | 93.048% |
| HST Global, Inc. | -140.9 Thousand USD | -378.839% |
| Wesana Health Holdings Inc. | -1.12 Million USD | 40.02% |
| Halberd Corporation | -75.05 Thousand USD | -799.025% |
| Enzolytics Inc. | -2.14 Million USD | 68.6% |
| Agentix Corp. | -1.37 Million USD | 50.814% |
| Resverlogix Corp. | -12.74 Million USD | 94.708% |
| Nuo Therapeutics, Inc. | -3.16 Million USD | 78.704% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | -425.04 Million USD | 99.841% |
| Enzon Pharmaceuticals, Inc. | -1.04 Million USD | 35.372% |
| Endonovo Therapeutics, Inc. | -2.91 Million USD | 76.889% |
| RespireRx Pharmaceuticals Inc. | -1.57 Million USD | 57.279% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -3.4 Million USD | 80.184% |
| AVAX Technologies, Inc. | 6.69 Million USD | 110.081% |
| Zenith Capital Corp. | -8.94 Million USD | 92.455% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | -3773.015% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -2.45 Million USD | 72.52% |
| WPD Pharmaceuticals Inc. | -171.5 Thousand USD | -293.4% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | 66.344% |
| Kadimastem Ltd | -3.04 Million USD | 77.807% |
| Helix BioMedix, Inc. | -984.05 Thousand USD | 31.435% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | -181.48 Thousand USD | -271.776% |
| LadRx Corporation | -3.82 Million USD | 82.354% |
| Cell Source, Inc. | -4.32 Million USD | 84.401% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | 1.781% |
| NovAccess Global Inc. | -2.46 Million USD | 72.648% |
| Affymax, Inc. | -15.04 Million USD | 95.516% |
| Itoco Inc. | -919.14 Thousand USD | 26.592% |
| Rasna Therapeutics, Inc. | -4.23 Million USD | 84.081% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | 39.703% |
| Mobile Lads Corp. | -554.55 Thousand USD | -21.669% |
| CytoDyn Inc. | -18.05 Million USD | 96.264% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -25.17 Thousand USD | -2580.644% |
| NanoSphere Health Sciences Inc. | -220.07 Thousand USD | -206.581% |
| Alseres Pharmaceuticals, Inc. | -564.72 Thousand USD | -19.478% |
| SYBLEU INC | -149.18 Thousand USD | -352.284% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | -1.81 Million USD | 62.852% |
| International Stem Cell Corporation | -663 Thousand USD | -1.767% |
| Bioxytran, Inc. | -3.82 Million USD | 82.338% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | -1181.759% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -20.34 Thousand USD | -3217.198% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -36.26 Million USD | 98.14% |
| Adhera Therapeutics, Inc. | -1.61 Million USD | 58.299% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -735.83 Thousand USD | 8.306% |
| Innovation Pharmaceuticals Inc. | -3.11 Million USD | 78.312% |
| Neutra Corp. | -229.48 Thousand USD | -194.013% |
| Windtree Therapeutics, Inc. | -17.53 Million USD | 96.153% |
| PureTech Health plc | -146.19 Million USD | 99.538% |
| Coeptis Therapeutics, Inc. | -21.49 Million USD | 96.86% |
| IXICO plc | -1.43 Million USD | 53.047% |
| IntelGenx Technologies Corp. | -9.49 Million USD | 92.891% |
| Gelesis Holdings, Inc. | -121.8 Million USD | 99.446% |
| CSL Limited | 3.81 Billion USD | 100.018% |
| Cellectis S.A. | -108.85 Million USD | 99.38% |